argenx is a biotechnology company that develops antibody-based therapies for severe autoimmune diseases, including its FcRn-blocker Vyvgart.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 9,300 | $8,917,863 | 0.0% |
| Steve Cohen / Point72 | 75 | Added +126% | 103,544 | $99,289,377 | 0.1% |
| Bridgewater | 55 | Added +1016% | 21,842 | $20,944,512 | 0.1% |
| Ancora | 42 | Added +233% | 20 | $19,178 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-10-27 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-10-15 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-10-14 | Gilbert Cisneros CA31 | BUY | $15,001 - $50,000 | PTR |
| 2026-03-30 | Alan Armstrong senate | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.